Cargando…

Dupilumab reduces local type 2 pro‐inflammatory biomarkers in chronic rhinosinusitis with nasal polyposis

BACKGROUND: Chronic rhinosinusitis with nasal polyposis (CRSwNP) is a type 2‐mediated inflammatory disease associated with significant clinical, social, and economic burdens and high unmet therapeutic need. Dupilumab, a fully human monoclonal antibody targeting the interleukin‐4 receptor α (IL‐4Rα)...

Descripción completa

Detalles Bibliográficos
Autores principales:	Jonstam, Karin, Swanson, Brian N., Mannent, Leda P., Cardell, Lars‐Olaf, Tian, Nian, Wang, Ying, Zhang, Donghui, Fan, Chunpeng, Holtappels, Gabriele, Hamilton, Jennifer D., Grabher, Annette, Graham, Neil M. H., Pirozzi, Gianluca, Bachert, Claus
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	ORIGINAL ARTICLES
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6590149/ https://www.ncbi.nlm.nih.gov/pubmed/30488542 http://dx.doi.org/10.1111/all.13685

Ejemplares similares

Genome wide gene expression analysis of nasal mucosa from patients with chronic rhinosinusitis and nasal polyposis stimulated with staphylococcal enterotoxin B
por: Perez Novo, Claudina, et al.
Publicado: (2015)

Extent of inflammation in severe nasal polyposis and effect of sinus surgery on inflammation
por: Jonstam, Karin, et al.
Publicado: (2020)

Effect of Dupilumab on Type 2 Biomarkers in Chronic Rhinosinusitis With Nasal Polyps: SINUS-52 Study Results
por: Bachert, Claus, et al.
Publicado: (2023)

Dupilumab efficacy in chronic rhinosinusitis with nasal polyps from SINUS‐52 is unaffected by eosinophilic status
por: Fujieda, Shigeharu, et al.
Publicado: (2021)

The Effect of Dupilumab on Intractable Chronic Rhinosinusitis with Nasal Polyps in Japan
por: Fujieda, Shigeharu, et al.
Publicado: (2020)

Efficacy of dupilumab in patients with a history of prior sinus surgery for chronic rhinosinusitis with nasal polyps
por: Hopkins, Claire, et al.
Publicado: (2021)

Data Mining of Free-Text Responses: An Innovative Approach to Analyzing Patient Perspectives on Treatment for Chronic Rhinosinusitis with Nasal Polyps in a Phase IIa Proof-of-Concept Study for Dupilumab
por: Khan, Asif H, et al.
Publicado: (2021)

Estimating Clinically Meaningful Change of Efficacy Outcomes in Inadequately Controlled Chronic Rhinosinusitis with Nasal Polyposis
por: Han, Joseph K., et al.
Publicado: (2021)

Twelve-year follow-up study after endoscopic sinus surgery in patients with chronic rhinosinusitis with nasal polyposis
por: Calus, Lien, et al.
Publicado: (2019)

Dupilumab‐induced skin‐associated side effects in patients with chronic rhinosinusitis with nasal polyposis
por: Chromy, David, et al.
Publicado: (2022)

Rhinosinusitis with nasal polyposis
por: Sharma, S.C.
Publicado: (2018)

COVID-19 in a patient with severe chronic rhinosinusitis with nasal polyps during therapy with dupilumab
por: Förster-Ruhrmann, Ulrike, et al.
Publicado: (2020)

Exacerbation of Eosinophilic Granulomatosis With Polyangiitis After Administering Dupilumab for Severe Asthma and Eosinophilic Rhinosinusitis With Nasal Polyposis
por: Tanaka, Shunya, et al.
Publicado: (2022)

Efficacy and safety of dupilumab in patients with uncontrolled severe chronic rhinosinusitis with nasal polyps and a clinical diagnosis of NSAID‐ERD: Results from two randomized placebo‐controlled phase 3 trials
por: Mullol, Joaquim, et al.
Publicado: (2021)

Pathophysiology of chronic rhinosinusitis, pharmaceutical therapy options
por: Bachert, Claus, et al.
Publicado: (2015)

Activation of Activin receptor-like kinases curbs mucosal inflammation and proliferation in chronic rhinosinusitis with nasal polyps
por: Tengroth, Lotta, et al.
Publicado: (2018)

The argument against the use of dupilumab in patients with limited polyp burden in chronic rhinosinusitis with nasal polyposis (CRSwNP)
por: Hardison, Scott A., et al.
Publicado: (2023)

AROMA: real-world global registry of dupilumab for chronic rhinosinusitis with nasal polyps
por: Siddiqui, Shahid, et al.
Publicado: (2022)

Dupilumab efficacy and biomarkers in chronic rhinosinusitis with nasal polyps: Association between dupilumab treatment effect on nasal polyp score and biomarkers of type 2 inflammation in patients with chronic rhinosinusitis with nasal polyps in the phase 3 SINUS‐24 and SINUS‐52 trials
por: Bachert, Claus, et al.
Publicado: (2022)

Chronic rhinosinusitis with nasal polyps is characterized by dysbacteriosis of the nasal microbiota
por: Chalermwatanachai, Thanit, et al.
Publicado: (2018)

Dupilumab in CRSwNP: Responder Analysis Using Clinically Meaningful Efficacy Outcome Thresholds
por: Chuang, Chien‐Chia, et al.
Publicado: (2021)

Subgroups in the treatment of nasal polyposis with dupilumab: A retrospective study
por: Bertlich, Mattis, et al.
Publicado: (2022)

Association of Mucosal Organisms with Patterns of Inflammation in Chronic Rhinosinusitis
por: Chalermwatanachai, Thanit, et al.
Publicado: (2015)

Management of Chronic Rhinosinusitis with Nasal Polyposis in the Era of Biologics
por: C Morse, Justin, et al.
Publicado: (2021)

Downregulation of peroxisome proliferator-activated receptors (PPARs) in nasal polyposis
por: Cardell, Lars-Olaf, et al.
Publicado: (2005)

Nasal allergen provocation test in nasal polyposis with and without allergy
por: Calus, Lien, et al.
Publicado: (2013)

Burden of Disease in Chronic Rhinosinusitis with Nasal Polyps
por: Bachert, Claus, et al.
Publicado: (2021)

Characterization of T-cell subpopulations in patients with chronic rhinosinusitis with nasal polyposis
por: Ickrath, Pascal, et al.
Publicado: (2017)

Chronic rhinosinusitis with nasal polyposis: the role of personalized and integrated medicine
por: Passali, Desiderio, et al.
Publicado: (2020)

Role and Function of Regulatory T Cell in Chronic Rhinosinusitis with Nasal Polyposis
por: Lei, Chenyang, et al.
Publicado: (2022)

Remission: does it already exist in chronic rhinosinusitis with nasal polyposis?
por: Chan, Yvonne, et al.
Publicado: (2023)

Rapid and sustained effects of dupilumab in severe chronic rhinosinusitis with nasal polyps
por: Hellings, Peter W., et al.
Publicado: (2022)

Dupilumab suppresses type 2 inflammatory biomarkers across multiple atopic, allergic diseases
por: Hamilton, Jennifer D., et al.
Publicado: (2021)

Short-Term Evaluation of Dupilumab Effects in Patients with Severe Asthma and Nasal Polyposis
por: Pelaia, Corrado, et al.
Publicado: (2021)

Cost burden and resource utilization in patients with chronic rhinosinusitis and nasal polyps
por: Bhattacharyya, Neil, et al.
Publicado: (2019)

Clinical Efficacy among Patients with Chronic Rhinosinusitis with Nasal Polyps and Clinical Features of Obstructive Lung Disease: Post Hoc Analysis of the Phase III SINUS-24 and SINUS-52 Studies
por: Maspero, Jorge F, et al.
Publicado: (2023)

Change in nasal congestion index after treatment in patients with chronic rhinosinusitis with nasal polyposis
por: Sahin-Onder, Serap, et al.
Publicado: (2016)

Biologics for the treatment of chronic rhinosinusitis with nasal polyps - state of the art
por: Ren, Lei, et al.
Publicado: (2019)

Chronic Rhinosinusitis Patients Show Accumulation of Genetic Variants in PARS2
por: Henmyr, Viktor, et al.
Publicado: (2016)

Molecular mechanisms of glucocorticoids action: implications for treatment of rhinosinusitis and nasal polyposis
por: Grzanka, Alicja, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_mtnoie48b2shcfiiqf2htfiake